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Abstract
Background: Previous studies showed an association between Coagulation Factor XII 46C>T
polymorphism and variation in FXII plasma levels, as 46C>T seems to affect the translation
efficiency. Case-control studies in Spanish samples indicated that genotype T/T is an independent
risk factor for venous thrombosis, ischemic stroke and acute coronary artery disease. In this study,
we tried to reaffirm the importance of 46C>T in two samples from Spain and Tunisia.
Findings: A Transmission Disequilibrium Test (TDT) based on 101 family trios from Barcelona
with one offspring affected by ischemic heart disease and a classical case-control study based on 76
patients with IHD and 118 healthy individuals from North and Centre-South Tunisia were
conducted. Subjects were genotyped for 46C>T and data were analyzed accordingly, revealing no
association in any of the two samples (TDT: P = 0.16, relative risk 1.17; case-control study: P =
0.59, odds ratio 1.36).
Conclusion: The results suggest that 46C>T is not a risk factor for ischemic heart disease in any
of the two analyzed samples and therefore the polymorphism seems not to be a universal risk
factor for cardiovascular diseases.
Findings
The gene of coagulation Factor (F) XVII has been repeat-
edly analysed in many epidemiological studies on cardio-
vascular (CV) genetic risk with controversial results. It has
been reported that FXII plasma levels exhibit a 67% of
heritability and that these levels are strongly determined
by F12 gene variants.[1] Although low FXII plasma levels
have been reported to affect the development of CV dis-
eases, it has been recently proposed that, rather than the
cause of thrombosis, these low levels are actually the
result of it. [2,3]
A highlighted F12 polymorphism is the 46C>T transition.
It seems that 46C>T affects the translation efficiency, lead-
ing to reduced FXII plasma levels.[4] This polymorphism
(with allele frequencies 0.8/0.2 in Caucasians) accounts
for 40% of the variance in FVII activity in a Spanish Med-
iterranean population and seems to fit a log additive
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model of inheritance with an allele dose-dependent
effect.[1,4]
Previous genetic association studies between 46C>T and
CV risk showed that genotype T/T increases significantly
the risk for venous thrombosis, ischemic stroke and acute
coronary artery disease in a Spanish population. [5-7] The
odds ratio in acute coronary artery disease was estimated
around 4.8.[7] Conversely, there are also studies that
either do not detect genetic association between this gen-
otype and CV risk or alternatively report association
between the C/C genotype and CV risk.[2,8]
In this context, this study provides additional data about
the allele frequency distribution of 46C>T in two new
Mediterranean samples. These data are used in an attempt
to confirm previous genetic association studies, by a dou-
ble epidemiological design: a family-based analysis
(Transmission Disequilibrium Test  TDT) applied in a
Spanish sample and a classical case-control study applied
in a Tunisian sample.
A total of 101 nuclear families (n = 302) with one off-
spring (93 males and 8 females) clinically diagnosed for
ischemic heart disease (IHD) were analyzed, all from the
area of Barcelona, Spain. A comprehensive description of
the families, diagnosis criteria and DNA extraction meth-
ods has been reported elsewhere.[9] Moreover, 76
patients with IHD complicated by myocardial infarction,
all from Monastir, Tunisia, as well as 118 unrelated
healthy autochthonous individuals from North and Cen-
tral-North Tunisia were also analyzed in an unmatched
case-control design.[10] This study has been performed in
accordance with the Ethical Committee guidelines of the
participating Hospitals and Universities and all subjects
participating in the study signed a written informed con-
sent.
Polymorphism 46C>T was genotyped by Real-Time PCR,
using the standard TaqMan® SNP genotyping assay proto-
col of Applied Biosystems for a total volume of 5 μl per
well. DNA amplification as well as fluorescence intensity
measurements of the final reaction product and data col-
lection were carried out with an ABI PRISM® 7900 HT
Sequence Detection System.
Allele frequencies in the Spanish IHD patients and their
parents as well as in patients and controls from Tunisia
were calculated directly. A TDT analysis was performed in
the IHD families from Barcelona, using the FBAT v2.0.2c
program.[11] In the Tunisian case-control study, associa-
tion was examined with Epi Info™ v3.4.3.[12] This pro-
gram was also used for the calculation of the relative risk
in the TDT analysis and the odds ratio (T/T vs. C/C and C/
T) in the case-control design. Sample power was calcu-
lated using QUANTO v1.2.3 assuming a CV disease prev-
alence of 0.07.[13]
Frequencies of the T allele in the Spanish and Tunisian
samples are shown in Table 1. In the Spanish families, the
TDT analysis indicated a low relative risk of 1.17 (95% CI:
0.75 <RR<1.82) for the T allele, without any significant
transmission to the patients (p = 0.16). Power calcula-
tions revealed that the minimum detectable risk our fam-
ily sample size (n = 101) could find was approximately
1.9 (with a power >80%). In the Tunisian sample, the esti-
mated odds ratio for the T/T genotype was 1.36 (95% CI:
0.36 < OR <4.93), without any significant association (p
= 0.59). Again, the minimum detectable effect our set of
76 patients and 118 controls could find was around 1.9.
Finally, no significant differences were found in any pair-
wise comparison of the data in Table 1.
Our study showed that the allele frequencies of the FXII
46C>T polymorphism are similar in the Spanish and
Tunisian samples, in accordance with the Caucasian pat-
tern. This suggests a stable presence of 46C>T in different
Mediterranean regions. On the other hand, our results
indicate the absence of association between 46C>T and
CV disease in both samples.
The similar allele frequency distributions between Span-
ish patients and parents and between Tunisian patients
and controls provide a first rough estimate of the lack of
association. Moreover, our Tunisian sample has enough
power (>99%) to detect an odds ratio of 4.8, as reported
Table 1: Allele and genotype frequencies of the 46C>T in the Spanish and Tunisian CV patients
Allele frequencies Genotype frequencies
C T CC CT TT N
Spain affected children 0.768 0.232 0.590 0.356 0.054 97
parents 0.799 0.201 0.638 0.321 0.040 137
Tunisia cases 0.770 0.230 0.593 0.354 0.053 76
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elsewhere, reinforcing the consistency of the lack of asso-
ciation detected.[7] As far as we know, this is the first time
the potential role of 46C>T is tested through a family-
based TDT analysis. Out findings confirm the negative
results of the case-control design, always taking into
account that our family trios have power only to detect
risks above 1.9.
The diverse results of previous studies regarding associa-
tion between polymorphism 46C>T and CV disease could
be explained, at least in part, by the differences in study
design, the definition of inclusion and exclusion criteria
and the number of participants. In our case, the low sam-
ple size in the TDT study and the lack of a matched case-
control design impose some caution in the interpretation
of our results.
In short, our results provide indirect evidence that 46C>T
is not a universal independent risk factor for CV diseases.
What seems to be well established is that the T allele
affects the variation of intermediate phenotypes (FXII
plasma levels). If this is true, then the diversity of results
in genetic association studies is hard to explain. This
observation leads us to adopt the idea that the low levels
of FXII are the consequence rather than the cause of the
disease, as has been recently suggested.[3] This idea finds
solid ground when combined with other independent
results on the lack of causality between FXII deficiency
and venous thrombosis. [14,15] In this context, 46C>T
polymorphism may not be a direct determinant of CV
risk.
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